IMCR News and Press, Immunocore Holdings plc From 05/26/22

P RESS RELEASE Immunocore announces upcoming presentations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Updated overall survival (OS) data from Ph ase 1b metastatic cutaneous melanoma trial O ral pr...

Medison Pharma Announces Extension of Multi-territorial Agreement with Immunocore and Expansion into Australia and New Zealand Canada NewsWire The latest geographic growth increases Medison's global footprint across 25 countries in four continents, further strengthenin...

Immunocore press release (NASDAQ:IMCR): Q1 GAAP EPS of -$0.48 beats by $0.60. Revenue of $29.56M (+171% Y/Y) beats by $21.4M. For further details see: Immunocore GAAP EPS of -$0.48 beats by $0.60, revenue of $29.56M beats by $21.4M

Immunocore Reports First Quarter 2022 Financial Results and Provides Business Update KIMMTRAK® ( tebentafusp-tebn ) approved in the United States and European Union for the treatment of unresectable or metastatic uveal melanoma ...

Immunocore to present at the 21 st Annual Needham Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 7 April 2022) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the dev...

It takes a tremendous amount of time and patience to get an experimental drug through the testing and approval process. What's more, drugs in clinical development have a 90% failure rate. Even after crossing that hurdle, the product still has to sell. But relative newbies Legend ...

P RESS RELEASE European Commission Approves KIMMTRAK ® ( tebentafusp ) for the treatment of unresectable or metastatic uveal melanoma KIMMTRAK is the first and only treatment approved in the E.U. to treat...

When you invest in a stock, you're not just investing in good numbers, or an exciting story. What you're really investing in is people. Who is leading your company? Where have they been, and where do they want to go? Our roundtable is excited about three healthcare companies with outsta...

Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...

Immunocore to present at Oppenheimer’s 32 nd Annual Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 9 March 2022) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering th...